PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
04 avr. 2024 01h00 HE
|
PolTREG S.A.
New biomarker may facilitate monitoring T1D patients’ healthIncrease in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw...
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 mars 2024 08h30 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27 mars 2024 08h00 HE
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
26 mars 2024 03h00 HE
|
Intravacc B.V.
First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
22 mars 2024 07h00 HE
|
OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21 mars 2024 07h58 HE
|
CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D
Theratechnologies entreprend l’augmentation de la dose dans l’essai clinique de phase I sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
21 mars 2024 07h30 HE
|
Theratechnologies
Le comité d’examen médical a approuvé la mise en place du recrutement de la prochaine cohorte de patientes, conformément au protocole d’optimisation des dosesUne première patiente du groupe qui en...
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21 mars 2024 07h30 HE
|
Theratechnologies
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial...
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
21 mars 2024 07h00 HE
|
OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
20 mars 2024 16h00 HE
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and...